Brad S Kahl

Brad S Kahl

UNVERIFIED PROFILE

Are you Brad S Kahl?   Register this Author

Register author
Brad S Kahl

Brad S Kahl

Publications by authors named "Brad S Kahl"

Are you Brad S Kahl?   Register this Author

100Publications

3587Reads

37Profile Views

An iatrogenic orphan?

Authors:
Brad S Kahl

Blood 2019 Oct;134(16):1273-1274

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood.2019002418DOI Listing
October 2019

Recent advances and future directions in mantle cell lymphoma research: report of the 2018 mantle cell lymphoma consortium workshop.

Leuk Lymphoma 2019 Aug 30;60(8):1853-1865. Epub 2019 Jan 30.

f GW Cancer Center, George Washington University , Washington , DC , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/10428194.2019.1571205DOI Listing
August 2019

Can We Exploit the Molecular Heterogeneity of Aggressive B Cell Lymphomas Into Effective New Therapies?

Clin Lymphoma Myeloma Leuk 2019 02 24;19(2):65-67. Epub 2018 Nov 24.

Department of Medicine, Washington University School of Medicine, St. Louis, MO.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clml.2018.11.017DOI Listing
February 2019

Loncastuximab tesirine in patients with B-cell non-Hodgkin lymphoma.

Authors:
Brad S Kahl

Clin Adv Hematol Oncol 2018 Nov;16(11):732-734

Lymphoma Program, Washington University School of Medicine, St Louis, Missouri.

View Article

Download full-text PDF

Source
November 2018

Current Approaches to Mantle Cell Lymphoma: Diagnosis, Prognosis, and Therapies.

Am Soc Clin Oncol Educ Book 2017 ;37:512-525

From Emory University, Atlanta, GA; City of Hope, Duarte, CA; Washington University School of Medicine, St. Louis, MO.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/EDBK_175448DOI Listing
December 2017

Follicular lymphoma: are we ready for a risk-adapted approach?

Authors:
Brad S Kahl

Hematology Am Soc Hematol Educ Program 2017 12;2017(1):358-364

Division of Oncology, Washington University School of Medicine, St. Louis, MO.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/asheducation-2017.1.358DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6142597PMC
December 2017

NR4A1 inhibition synergizes with ibrutinib in killing mantle cell lymphoma cells.

Blood Cancer J 2017 11 23;7(12):632. Epub 2017 Nov 23.

Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI, 53792, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41408-017-0005-zDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5802686PMC
November 2017

Recent advances and future directions in mantle cell lymphoma research: report of the 2016 mantle cell lymphoma consortium workshop.

Leuk Lymphoma 2017 07 31;58(7):1561-1569. Epub 2017 Jan 31.

e Department of Medicine, George Washington University , Washington DC , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/10428194.2017.1283036DOI Listing
July 2017

Investigator and independent review committee exploratory assessment and verification of tumor response in a non-Hodgkin lymphoma study.

Leuk Lymphoma 2017 06 10;58(6):1332-1340. Epub 2016 Oct 10.

f Division of Hematology and Oncology , Georgetown University , Washington , DC , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/10428194.2016.1233535DOI Listing
June 2017

Idelalisib is effective in patients with high-risk follicular lymphoma and early relapse after initial chemoimmunotherapy.

Blood 2017 06 21;129(22):3037-3039. Epub 2017 Mar 21.

Department of Medicine, James P. Wilmot Cancer Center, University of Rochester, Rochester, NY; and.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2016-12-757740DOI Listing
June 2017

Hodgkin Lymphoma: Current Status and Clinical Trial Recommendations.

J Natl Cancer Inst 2017 04 31;109(4). Epub 2016 Dec 31.

Affiliations of authors: NYU Perlmutter Cancer Center, New York, NY (CSD); BC Cancer Agency Centre for Lymphoid Cancer, Vancouver, BC, Canada (JMC); Wilmot Cancer Center and Division of Hematology/Oncology, University of Rochester Medical Center, Rochester, NY (JWF); Department of Medicine, Weil Cornell University, New York, NY (JPL); Oncology Division, Department of Medicine, Washington University, St. Louis, MO (BSK, NLB); Division of Cancer Treatment and Diagnosis (RFL) and Coordinating Center for Clinical Trials (LB), Tufts Cancer Center and Division of Hematology/Oncology, Tufts University School of Medicine, Boston, MA (AME); Stanford Cancer Institute, Stanford University Medical School, Stanford, CA (RTH); Division of Pediatric Hematology/Oncology/Stem Cell Transplant, Columbia University Medical Center, New York, NY (KMK); Department of Medicine, University of Arizona Cancer Center, Tucson, AZ (DOP); Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY (AY); Department of Radiology, Mount Sinai Hospital, New York, NY (LK).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jnci/djw249DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6059238PMC
April 2017

Recommendations for Clinical Trial Development in Follicular Lymphoma.

J Natl Cancer Inst 2017 03 31;109(3). Epub 2016 Dec 31.

Affiliations of authors: The Ohio State University, Columbus, OH (KM); University of Rochester Medical Center, Rochester, NY (PMB); Georgetown University Hospital, Washington, DC (BDC); Division of Cancer Treatment and Diagnosis (RFL) and Coordinating Center for Clinical Trials (LB), National Cancer Institute, Bethesda, MD; Department of Medicine, Oncology Division, Washington University, St. Louis, MO (BSK); Department of Medicine, Weil Cornell University, New York, NY (JPL); The University of Texas MD Anderson Cancer Center, Houston, TX (NF); Northwestern University, Chicago, IL (LIG); University of Iowa, Iowa City, IA (BKL); Wilmot Cancer Center and Division of Hematology/Oncology, University of Rochester, Rochester, NY (JWF); Mayo Clinic, Rochester, MN (SMA).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jnci/djw255DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6059137PMC
March 2017

Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma.

J Clin Oncol 2017 Mar 17;35(8):826-833. Epub 2017 Jan 17.

Matthew S. Davids, Dana-Farber Cancer Institute, Boston, MA; Andrew W. Roberts, John F. Seymour, and Mary Ann Anderson, University of Melbourne; Andrew W. Roberts and Mary Ann Anderson, Royal Melbourne Hospital and Eliza Hall Institute of Medical Research; and John F. Seymour, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia; John M. Pagel, Swedish Cancer Institute, Seattle, WA; Brad S. Kahl, Washington University Medical School, St Louis, MO; William G. Wierda, University of Texas MD Anderson Cancer Center, Houston, TX; Soham Puvvada, University of Arizona, Tucson, AZ; Thomas J. Kipps, University of California San Diego, San Diego, CA; Ahmed Hamed Salem, Martin Dunbar, Ming Zhu, Jeremy A. Ross, Lori Gressick, Monali Desai, Su Young Kim, Maria Verdugo, Rod A. Humerickhouse, and Gary B. Gordon, AbbVie, Chicago, IL; Ahmed Hamed Salem, Faculty of Pharmacy, Ain Shams University, Cairo, Egypt; Franklin Peale, Genentech, South San Francisco, CA; John F. Gerecitano, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical Center, New York, NY.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.70.4320DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5455685PMC
March 2017

Recommendations for Clinical Trial Development in Mantle Cell Lymphoma.

J Natl Cancer Inst 2017 01 31;109(1). Epub 2016 Dec 31.

Affiliations of authors: Division of Hematology and Medical Oncology, Oregon Health and Science (OHSU) University Knight Cancer Institute, Portland, OR (SES); Clinical Research Division, Fred Hutchinson Cancer Research Center/ Department of Medicine, Division of Medical Oncology, University of Washington, Seattle, WA (BGT, AKG); Department of Medicine, Weill Cornell Medicine, New York, NY (PM, JPL); John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, NJ (AHG); Department of Medicine III, Klinikum der Universität München, Campus Grosshadern, Munich, Germany (MPD); Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA (ML); Wilmot Cancer Center and Division of Hematology/Oncology, University of Rochester, Rochester, NY (JWF); Coordinating Center for Clinical Trials, National Cancer Institute, National Institutes of Health, Bethesda, MD (LB); HIV and AIDS Malignancy Branch, Center for Cancer Research, and Clinical Investigations Branch, Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, MD (RFL); Department of Medicine, Oncology Division, Washington University, St. Louis, MO (BSK); Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH (MRS).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jnci/djw263DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6059122PMC
January 2017

General Biomarker Recommendations for Lymphoma.

J Natl Cancer Inst 2016 12 16;108(12). Epub 2016 Dec 16.

Department of Laboratory Medicine and Pathology, Mayo Clinic, Scottsdale, AZ (LR), Department of Pathology and Laboratory Medicine, University of North Carolina Medical School, Chapel Hill, NC (YF), Center for Cancer Research, National Cancer Institute, Bethesda, MD (LMS), Department of Medicine, Weill Cornell Medical College, New York, NY (AM), Department of Pathology and Laboratory Medicine, British Columbia Cancer Agency, Vancouver, BC, Canada (RG), Clinical Cancer Research Unit, Princess Margaret Cancer Centre, University of Toronto, Toronto, Ontario, Canada (MC), Coordinating Center for Clinical Trials, National Cancer Institute, Bethesda, MD (LB), Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, NE (KF), Department of Pathology and Laboratory Medicine, Cleveland Clinic Foundation, Cleveland, OH (ED), Department of Pathology, City of Hope Medical Center, Duarte, CA (JWCC), Biometrics Research Branch, National Cancer Institute, Bethesda, MD (LM), Department of Medicine, Weill Cornell Medicine, New York, NY (JPL), Department of Medicine, Oncology Division, Washington University, St. Louis, MO (BSK), Clinical Investigations Branch, Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, MD (RFL), Wilmot Cancer Center and Division of Hematology/Oncology, University of Rochester, Rochester, NY (JWF), Department of Radiology, Mount Sinai Medical Center New York, NY (LK).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jnci/djw250DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6080362PMC
December 2016

Beyond RCHOP: A Blueprint for Diffuse Large B Cell Lymphoma Research.

J Natl Cancer Inst 2016 12 16;108(12). Epub 2016 Dec 16.

Department of Medicine, Mayo Clinic, Rochester, MN (GSN); Department of Internal Medicine, Ohio State University, Columbus, OH (KAB); Department of Medicine, Oncology Division, Washington University, St. Louis, MO (BSK); Wilmot Cancer Center and Division of Hematology/Oncology, University of Rochester, Rochester, NY (JWF); Coordinating Center for Clinical Trials (LB), Division of Cancer Treatment and Diagnosis (RFL), and Center for Cancer Research (WHW), National Cancer Institute, National Institute of Health, Bethesda, MD; Division of Oncology, University of Washington, Seattle WA (DGM); British Colombia Cancer Agency, Vancouver, BC (LHS); Department of Medicine, University of Virginia, Charlottesville, VA (MEW); Department of Medicine, Weil Cornell University, New York, NY (JPL); Department of Medicine, University of Chicago, Chicago, IL (SMS).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jnci/djw257DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6080361PMC
December 2016

Longitudinal Body Composition Changes in Diffuse Large B-cell Lymphoma Survivors: A Retrospective Cohort Study of United States Veterans.

J Natl Cancer Inst 2016 11 5;108(11). Epub 2016 Jul 5.

Affiliations of authors: Research Service, St. Louis Veterans Affairs Medical Center, St. Louis, MO (DYX, SL, KO, KMS, WL, KRC); Division of Public Health Sciences, Department of Surgery (KRC), and Division of Oncology, Department of Internal Medicine (SL, KO, KMS, PR, BSK, AFC, TAF, KRC), Washington University School of Medicine (DYX), St. Louis, MO; Department of Emergency Medicine, University of Michigan Health System, Ann Arbor, MI (AG); Division of Oncology, Department of Medicine, Stanford University School of Medicine/Stanford Cancer Institute, Stanford, CA (RCL).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jnci/djw145DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5241900PMC
November 2016

BV for HL: can the responses last?

Authors:
Brad S Kahl

Blood 2016 09;128(12):1540-1

WASHINGTON UNIVERSITY SCHOOL OF MEDICINE.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2016-08-730374DOI Listing
September 2016

Advances and issues in mantle cell lymphoma research: report of the 2014 Mantle Cell Lymphoma Consortium Workshop.

Leuk Lymphoma 2015 25;56(9):2505-11. Epub 2015 May 25.

e H. Lee Moffitt Cancer Center and Research Institute , Tampa , FL , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3109/10428194.2015.1045903DOI Listing
August 2016

US Intergroup Trial of Response-Adapted Therapy for Stage III to IV Hodgkin Lymphoma Using Early Interim Fluorodeoxyglucose-Positron Emission Tomography Imaging: Southwest Oncology Group S0816.

J Clin Oncol 2016 06 11;34(17):2020-7. Epub 2016 Apr 11.

Oliver W. Press, Fred Hutchinson Cancer Research Center, and the University of Washington; Hongli Li and Michael LeBlanc, Fred Hutchinson Cancer Research Center, Seattle, WA; Heiko Schöder, David J. Straus, Craig H. Moskowitz, and Ariela Noy, Memorial Sloan Kettering Cancer Center; John P. Leonard, Weill Cornell Medical College and New York Presbyterian Hospital, New York City; Paul M. Barr and Jonathan W. Friedberg, University of Rochester Medical Center, Rochester, NY; Lisa M. Rimsza, University of Arizona, Tucson, AZ; Nancy L. Bartlett and Brad S. Kahl, Washington University School of Medicine, St. Louis, MO; Andrew M. Evens, Tufts Medical Center; Ann S. LaCasce, Dana-Farber Cancer Institute, Boston, MA; Erik S. Mittra, Stanford University Medical Center, Stanford, CA; John W. Sweetenham, Huntsman Cancer Hospital, Salt Lake City, UT; Michelle A. Fanale, University of Texas MD Anderson Cancer Center, Houston, TX; Michael V. Knopp, The Ohio State University, Columbus; Eric D. Hsi, Cleveland Clinic Foundation; James R. Cook, Cleveland Clinic, Cleveland, OH; Mary Jo Lechowicz, Winship Cancer Institute of Emory University, Atlanta, GA; Randy D. Gascoyne, British Columbia Cancer Agency, Vancouver, BC; Bruce D. Cheson, Georgetown University Hospital, Washington DC; and Richard I. Fisher, Fox Chase Cancer Center, Philadelphia, PA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2015.63.1119DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4966513PMC
June 2016

Follicular lymphoma: evolving therapeutic strategies.

Blood 2016 04 17;127(17):2055-63. Epub 2016 Mar 17.

Department of Pathology and Laboratory Medicine, University of Wisconsin School of Medicine, Madison, WI.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2015-11-624288DOI Listing
April 2016

Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia.

N Engl J Med 2016 Jan 6;374(4):311-22. Epub 2015 Dec 6.

From the Department of Clinical Haematology and the Bone Marrow Transplantation Unit, Royal Melbourne Hospital (A.W.R., M.A.A.), the Division of Cancer and Haematology, Walter and Eliza Hall Institute of Medical Research (A.W.R., M.A.A.), and the Victorian Comprehensive Cancer Centre (A.W.R., J.F.S.), Parkville, VIC, and the University of Melbourne (A.W.R., J.F.S.) and Peter MacCallum Cancer Centre (J.F.S.), Melbourne, VIC - all in Australia; Dana-Farber Cancer Institute, Boston (M.S.D., J.R.B.); the Swedish Medical Center, Seattle (J.M.P.); Washington University, St. Louis (B.S.K.); University of Arizona, Tucson (S.D.P.); Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York (J.F.G.); University of California, San Diego, San Diego (T.J.K.); AbbVie, North Chicago, IL (L.G., S.W., M.D., M.Z., M.B.D., E.C., S.H.E., R.A.H.); and University of Texas M.D. Anderson Cancer Center, Houston (W.G.W.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1513257DOI Listing
January 2016

Current treatment approaches in follicular lymphoma.

Authors:
Brad S Kahl

Clin Adv Hematol Oncol 2015 Nov;13(11):740-3

Washington University School of Medicine, St. Louis, Missouri.

View Article

Download full-text PDF

Source
November 2015

Phase II Intergroup Trial of Alisertib in Relapsed and Refractory Peripheral T-Cell Lymphoma and Transformed Mycosis Fungoides: SWOG 1108.

J Clin Oncol 2015 Jul 15;33(21):2399-404. Epub 2015 Jun 15.

Paul M. Barr and Jonathan W. Friedberg, University of Rochester, Rochester; Steven M. Horwitz, Memorial Sloan Kettering Cancer Center, New York, NY; Hongli Li and Michael LeBlanc, SWOG Statistical Office, Seattle, WA; Catherine Spier, University of Arizona College of Medicine, Tucson, AZ; Daruka Mahadevan, Mansoor Ul Haq, and Bryan D. Huber, University of Tennessee Health Sciences Center, Memphis, TN; Christopher R. Flowers, Emory University, Atlanta, GA; Nina D. Wagner-Johnston and Nancy L. Bartlett, Washington University School of Medicine, St. Louis, MO; Richard I. Fisher, Temple University, Philadelphia, PA; Bruce D. Cheson, Georgetown University Hospital, Washington, DC; Sonali M. Smith, The University of Chicago, Chicago, IL; and Brad S. Kahl, University of Wisconsin, Madison, WI.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2014.60.6327DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4500834PMC
July 2015

Randomized Phase III Trial Comparing ABVD Plus Radiotherapy With the Stanford V Regimen in Patients With Stages I or II Locally Extensive, Bulky Mediastinal Hodgkin Lymphoma: A Subset Analysis of the North American Intergroup E2496 Trial.

J Clin Oncol 2015 Jun 20;33(17):1936-42. Epub 2015 Apr 20.

Ranjana H. Advani, Richard T. Hoppe, and Sandra J. Horning, Stanford University, Stanford; Joseph M. Tuscano, University of California, Davis Cancer Center, Sacramento, CA; Fangxin Hong, Dana-Farber Cancer Institute, Boston, MA; Richard I. Fisher and Jonathan W. Friedberg, University of Rochester, Rochester, NY; Nancy L. Bartlett, Washington University School of Medicine, St Louis, MO; K. Sue Robinson, Queen Elizabeth II Health Science Center, Halifax, Nova Scotia; Randy D. Gascoyne, British Columbia Cancer Agency, Vancouver, British Columbia; Douglas A. Stewart, Tim Baker Cancer Institute, Calgary, Alberta, Canada; Henry Wagner Jr, Penn State Cancer Institute, Hershey, PA; Patrick J. Stiff, Loyola University Medical Center, Maywood; Leo I. Gordon, Northwestern University, Chicago, IL; Bruce D. Cheson, Georgetown University Hospital, Washington, DC; Brad S. Kahl, University of Wisconsin, Madison, WI; Kristie A. Blum, Ohio State University, Columbus, OH; and Thomas M. Habermann, Mayo Clinic, Rochester, MN.

View Article

Download full-text PDF

Source
http://jco.ascopubs.org/content/early/2015/04/15/JCO.2014.57
Web Search
http://jco.ascopubs.org/cgi/doi/10.1200/JCO.2014.57.8138
Publisher Site
http://dx.doi.org/10.1200/JCO.2014.57.8138DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4451176PMC
June 2015

Mantle Cell Lymphoma: First-line Therapy in Patients Not Eligible for Stem Cell Transplantation.

Curr Treat Options Oncol 2015 Jun;16(6):29

Department of Medicine, Division of Hematology/Oncology, University of Wisconsin School of Medicine and Public Health, 1111 Highland Ave. 4059 WIMR, Madison, WI, 53705, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11864-015-0343-7DOI Listing
June 2015

Anxiety and health-related quality of life among patients with low-tumor burden non-Hodgkin lymphoma randomly assigned to two different rituximab dosing regimens: results from ECOG trial E4402 (RESORT).

J Clin Oncol 2015 Mar 20;33(7):740-8. Epub 2015 Jan 20.

Lynne I. Wagner and David Cella, Northwestern University Feinberg School of Medicine, Chicago, IL; Fengmin Zhao, Fangxin Hong, Dana-Farber Cancer Institute, Boston, MA; Michael E. Williams, University of Virginia, Charlottesville, VA; John C. Krauss, University of Michigan, Ann Arbor, MI; Ranjana H. Advani, Stanford University, Stanford; Sandra J. Horning, Genentech, South San Francisco, CA; Ronald S. Go, Gunderson Health System, La Crosse; Brad S. Kahl, University of Wisconsin, Madison, WI; Thomas M. Habermann, Mayo Clinic, Rochester; Joseph W. Leach, Metro Minnesota Community Clinical Oncology Program, Minneapolis, MN; Brian O'Connor, Frederick Memorial Health System, Frederick, MD; Stephen J. Schuster, University of Pennsylvania, Philadelphia, PA; and Randy D. Gascoyne, British Columbia Cancer Agency, Vancouver, BC, Canada.

View Article

Download full-text PDF

Source
http://jco.ascopubs.org/content/33/7/740.full.pdf
Web Search
http://jco.ascopubs.org/cgi/doi/10.1200/JCO.2014.57.6801
Publisher Site
http://dx.doi.org/10.1200/JCO.2014.57.6801DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4334777PMC
March 2015

Mantle cell lymphoma-management in evolution.

Chin Clin Oncol 2015 Mar;4(1)

Department of Medicine, Division of Hematology/Oncology, University of Wisconsin School of Medicine and Public Health and the UW Carbone Cancer Center, University of Wisconsin, Madison, WI, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3978/j.issn.2304-3865.2014.08.06DOI Listing
March 2015

Central nervous system involvement in diffuse large B-cell lymphoma: an analysis of risks and prevention strategies in the post-rituximab era.

Leuk Lymphoma 2014 Oct 24;55(10):2228-40. Epub 2014 Feb 24.

UW Carbone Cancer Center, Division of Hematology/Oncology, Department of Medicine, University of Wisconsin School of Medicine and Public Health , Madison, WI , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3109/10428194.2013.869326DOI Listing
October 2014

Recent advances in mantle cell lymphoma: report of the 2013 Mantle Cell Lymphoma Consortium Workshop.

Leuk Lymphoma 2014 Oct 17;55(10):2262-70. Epub 2014 Apr 17.

Northwestern University Feinberg School of Medicine and the Robert H. Lurie Comprehensive Cancer Center , Chicago, IL , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3109/10428194.2013.876634DOI Listing
October 2014

Rituximab extended schedule or re-treatment trial for low-tumor burden follicular lymphoma: eastern cooperative oncology group protocol e4402.

J Clin Oncol 2014 Oct 25;32(28):3096-102. Epub 2014 Aug 25.

Brad S. Kahl, University of Wisconsin, Madison; Christopher G. Peterson, Aspirus Regional Cancer Center, Wausau; Matthias Weiss, Marshfield Clinic, Marshfield, WI; Fangxin Hong, Dana-Farber Cancer Institute, Boston, MA; Michael E. Williams, University of Virginia, Charlottesville, VA; Randy D. Gascoyne, British Columbia Cancer Agency, Vancouver, British Columbia, Canada; Lynne I. Wagner, Northwestern University, Chicago, IL; John C. Krauss, University of Michigan, Ann Arbor, MI; Thomas M. Habermann, Mayo Clinic, Rochester; Mark D. Sborov, Fairview-Southdale Hospital, St Louis Park, MN; Lode J. Swinnen, Johns Hopkins University, Baltimore, MD; Stephen J. Schuster, University of Pennsylvania, Philadelphia; W. Christopher Ehmann, Penn State Cancer Institute, Hershey, PA; S. Eric Martin, Christiana Care Community Clinical Oncology Program and Helen F. Graham Cancer Network, Newark, DE; and Sandra J. Horning, Genentech, South San Francisco, CA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2014.56.5853DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4171355PMC
October 2014

Emerging therapy for the treatment of mantle cell lymphoma.

J Natl Compr Canc Netw 2014 Sep;12(9):1311-8; quiz 1318

From the Department of Medicine, Division of Hematology/Oncology, University of Wisconsin School of Medicine and Public Health, and the UW Carbone Cancer Center, University of Wisconsin, Madison, Wisconsin.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.6004/jnccn.2014.0126DOI Listing
September 2014

Bulky aggressive B-cell lymphoma: to radiate or not to radiate--that is the question.

Authors:
Brad S Kahl

J Clin Oncol 2014 Apr 18;32(11):1097-8. Epub 2014 Feb 18.

University of Wisconsin School of Medicine and Public Health, Madison, WI.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2013.54.1730DOI Listing
April 2014

PI3-kinase inhibitors in chronic lymphocytic leukemia.

Curr Hematol Malig Rep 2014 Mar;9(1):33-43

University of Wisconsin School of Medicine and Public Health, 1111 Highland Ave., 4007 Wisconsin Institute for Medical Research, Madison, WI, 53705, USA,

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11899-013-0189-7DOI Listing
March 2014

Integrating emerging treatment options in mantle cell lymphoma: introduction.

Authors:
Brad S Kahl

Clin Adv Hematol Oncol 2013 Dec;11 Suppl 19(12):2-3

UW Carbone Cancer Center Madison, WI.

View Article

Download full-text PDF

Source
December 2013

Frontline management strategies for older MCL patients.

Authors:
Brad S Kahl

Clin Adv Hematol Oncol 2013 Dec;11 Suppl 19(12):6-8

UW Carbone Cancer Center, Madison, WI.

View Article

Download full-text PDF

Source
December 2013

Integrating emerging treatment options in mantle cell lymphoma.

Clin Adv Hematol Oncol 2013 Dec;11(12 Suppl 19):1-15

UW Carbone Cancer Center, Madison, Wisconsin.

View Article

Download full-text PDF

Source
December 2013

Immunohistochemical evaluation of MYC expression in mantle cell lymphoma.

Histopathology 2013 Oct 8;63(4):499-508. Epub 2013 Aug 8.

Department of Pathology and Laboratory Medicine, University of Wisconsin, Madison, WI, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/his.12207DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3871984PMC
October 2013

Autologous transplantation as consolidation for aggressive non-Hodgkin's lymphoma.

N Engl J Med 2013 Oct;369(18):1681-90

From Loyola University Medical Center, Maywood, IL (P.J.S., K.P.B.); Southwest Oncology Group Statistical Center, Fred Hutchinson Cancer Research Center, Seattle (J.M.U., M.L.); Cleveland Clinic, Cleveland (J.R.C., R.R.T.); University of Rochester, Rochester, NY (L.S.C., J.W.F., R.I.F.); Queen Elizabeth II Health Sciences Centre and Dalhousie University, Halifax, NS (S.C.), University of Calgary-Tom Baker Cancer Centre, Calgary, AB (D.A.S.), and Margaret and Charles Juravinski Cancer Centre, Hamilton, ON (D.M.) - all in Canada; University of North Carolina at Chapel Hill, Chapel Hill (T.C.S.); Ohio State University Medical Center, Columbus (P.P.); Northwestern University, Chicago (J.N.W.); University of Wisconsin, Madison (B.S.K.); University of Arizona, Tucson (T.P.M., L.M.R.); Louisiana State University Health Sciences Center, Shreveport (G.M.M.); City of Hope Medical Center, Duarte, CA (S.J.F.); and Fox Chase Cancer Center-Temple Health, Temple University School of Medicine, Philadelphia (R.I.F.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1301077DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3985418PMC
October 2013

Recent advances in mantle cell lymphoma: report of the 2012 Mantle Cell Lymphoma Consortium Workshop.

Leuk Lymphoma 2013 Sep 4;54(9):1882-90. Epub 2013 Mar 4.

University of Virginia Health System, Charlottesville, VA, USA.

View Article

Download full-text PDF

Source
http://www.tandfonline.com/doi/full/10.3109/10428194.2013.77
Publisher Site
http://dx.doi.org/10.3109/10428194.2013.771400DOI Listing
September 2013

What is the best initial therapy for a patient with symptomatic low-grade follicular lymphoma?

Cancer J 2012 Sep-Oct;18(5):383-9

Division of Hematology/Oncology, Department of Medicine, University of Wisconsin School of Medicine and Public Health, and the UW Carbone Cancer Center, Madison, WI 53705, USA.

View Article

Download full-text PDF

Source
https://insights.ovid.com/crossref?an=00130404-201209000-000
Publisher Site
http://dx.doi.org/10.1097/PPO.0b013e31826aed6dDOI Listing
April 2013

Incremental value in outcome prediction with gene expression-based signatures in diffuse large B-cell lymphoma.

Blood 2013 Jan 16;121(1):156-8. Epub 2012 Nov 16.

Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Harvard School of Public Health, Boston, MA 02115, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2012-08-450106DOI Listing
January 2013

The future of B-cell lymphoma therapy: the B-cell receptor and its downstream pathways.

Curr Hematol Malig Rep 2012 Sep;7(3):216-20

University of Wisconsin, Madison, WI 53705, USA.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s11899-012-0127-0
Publisher Site
http://dx.doi.org/10.1007/s11899-012-0127-0DOI Listing
September 2012

Bendamustine: more ammunition in the battle against mantle cell lymphoma.

Leuk Lymphoma 2012 Jul 31;53(7):1249-50. Epub 2012 Jan 31.

Department of Medicine, University of Wisconsin School of Medicine and Public Health and UW Carbone Cancer Center, Madison, WI 53705, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3109/10428194.2011.654342DOI Listing
July 2012

Microscale functional cytomics for studying hematologic cancers.

Blood 2012 Mar 18;119(10):e76-85. Epub 2012 Jan 18.

Department of Biomedical Engineering, University of Wisconsin-Madison, 53705, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2011-10-384347DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3311264PMC
March 2012